Daily Archives: January 2, 2014

San Jose, California (PRWEB) January 02, 2014

Follow us on LinkedIn DNA Gene chips or DNA microarrays are small chips that are engrafted with DNA molecules. This advanced approach allows researchers to compare gene expressions in multiple cell types, identify active or switched-off genes, and compare various active genes under different settings. The growing focus on genetic testing and screening against a backdrop of increasing popularity of personalized medicine, is expected to drive demand for DNA gene chips. Growing popularity of preventive healthcare practices is also expected to help expand the use of DNA gene chips in preventative genetic diagnostics.

The trend report titled DNA Gene Chips announced by Global Industry Analysts Inc., is a focused research paper which provides cursory insights into the technology, its evolution, applications, and future prospects, in addition to providing coverage on corporate initiatives of key companies worldwide. The report also provides global market estimates and projections for DNA & Gene Chip (Microarray) in US dollars for years 2012 through 2017. Also covered are companies such as Affymetrix Inc., Agilent Technologies Inc., Illumina Inc., and Sequenom Inc., among others.

For more details about this trend report, please visit http://www.strategyr.com/TrendReport.asp?code=146088.

About Global Industry Analysts, Inc. Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc. Telephone: 408-528-9966 Fax: 408-528-9977 Email: press(at)StrategyR(dot)com Web Site: http://www.StrategyR.com/

###

Read the original:
Increasing Investments in Molecular Biology Research Drives the Market for DNA Gene Chips, According to a New Trend ...

PUBLIC RELEASE DATE:

2-Jan-2014

Contact: Lynn Celmer lcelmer@aasmnet.org 630-737-9700 American Academy of Sleep Medicine

DARIEN, IL A new study conducted across Europe found an extraordinary association between narcolepsy and a specific gene variant related to the immune system.

The modified genome-wide association study involved 1,261 people with narcolepsy, representing nearly 90 percent of European patients suffering from narcolepsy with cataplexy who have complete diagnostic work-up and DNA available. They were matched with 1,422 controls. High-resolution genotyping identified genetic variants including those in the human leukocyte antigen (HLA) system, which contains genes related to immune system function. Analysis was performed by logistic regression.

Results show that participants with the HLA allele DQB1*06:02 were 251 times more likely to have narcolepsy with cataplexy than participants without the gene variant. DQB1*06:02 had a remarkably high negative predictive value of 99.32 percent, which means that nearly 100 percent of narcolepsy with cataplexy patients are DQB1*06:02 positive. Four other DQB1 alleles provided protection against narcolepsy, strongly supporting a causal role for DQB1 in narcolepsy.

"For the first time we have tested the HLA association all over Europe," said principal investigator and lead author Mehdi Tafti, professor in the Center for Integrative Genomics at the University of Lausanne and Lausanne Hospital in Switzerland. "This almost 100 percent association with HLA is somehow unique to narcolepsy and suggests a causal implication."

Recent studies suggest that narcolepsy may be caused by an autoimmune response to an environmental trigger such as an infection. In people who are genetically susceptible to narcolepsy, the immune system may respond to the trigger by mistakenly attacking and destroying brain cells that make hypocretin, a hormone that helps promote alertness.

The authors noted that DQB1*06:02 is a common gene variant that is present in about 20 percent of the general European population. As a result, DQB1*06:02 had a low positive predictive value of only 65.68 percent. However, they suggested that high-resolution genotyping could play a valuable role in diagnosing patients suspected of having narcolepsy and evaluating at-risk populations.

"For clinicians these findings indicate they should reconsider the diagnosis of narcolepsy with cataplexy in HLA DQB1*06:02 negative patients," said American Academy of Sleep Medicine spokesperson Dr. Nathaniel Watson.

The rest is here:
Study supports a causal role in narcolepsy for a common genetic variant